OABI logo

OMNIAB INC

OABINASDAQ
🏆 #2751 by market capUS Equity
$735.61▲ $57.82 (+7.86%)
Simulated price
🔔
Track OABI
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 7.9%
7d▲ 14881.9%
14d▲ 16810.6%
30d▲ 16356.6%
ytd▲ 39662.7%
1y▲ 45732.4%
🏦Market Cap
$691M
Small Cap
📈Revenue Growth (YoY)
-29.3%
Declining
📊Gross Margin
50.5%
Healthy
💵FCF Margin
-47.2%
Thin
⚖️P/S Ratio
18.0x
Expensive
Otter Score
56
Weak

Trading Snapshot

Day Range
$727.73 – $743.39
52-Week Range
$1.30 – $5.43
Volume
$3.11B
Avg Volume
$3.28B
Shares Outstanding
145.0M
Next Earnings
Oct 26, 2026

Fundamentals Snapshot

Annual Revenue
$19M
Last Q Revenue
$13M
P/E Ratio
-13.2
P/S Ratio
18.0x
EPS (TTM)
$-0.34
Dividend Yield
0.00%
Dilution (1yr)
+21.9%

Why Investors Own OABI

  • ✓High-growth profile — revenue up +6.8% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 32% gross margin and 14% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

OABI logo

OMNIAB INC

OABI
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$19M▼ −29.3% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
-18.2%▼ −118.2% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$72M▼ −4.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$37M▼ −10.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
127.8M▲ +21.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$5M▲ +$756K YoY
StockOtter · stockotter.space

About OMNIAB INC

OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
56/100

Analyst Price Target

ⓘ
Average Target
$979.46
▲ +33.1% Upside
High Target$1,212.37
Low Target$757.36
Based on 15 analysts

Latest News & Updates

🚀
MarketWatch·2h ago

OMNIAB INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
CNBC·5h ago

Analysts lift OABI price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

OMNIAB INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.